Immunome Surges 7.8% on CEO's $1M Stock Purchase and Biotech Sector Optimism

Summary
• Immunome (IMNM) surges 7.8% to $21.51, breaking above its 52-week high of $25.30
• CEO Clay Siegall acquires 46,511 shares for ~$999,986, boosting ownership by 5.77%
• Biotech sector gains momentum as AMGN (Amgen) leads with 1.35% intraday rise

Immunome’s sharp intraday rally reflects a confluence of insider confidence and sector-wide optimism. The stock’s 7.8% surge to $21.51—its highest level since November—coincides with CEO Clay Siegall’s $1M open-market purchase and broader biotech sector strength. With the stock trading above key technical levels and a bullish RSI reading, investors are weighing the implications of executive conviction and clinical progress in varegacestat trials.

CEO's $1M Open-Market Buy Sparks Rally
Immunome’s 7.8% intraday surge is directly tied to CEO Clay Siegall’s $999,986 open-market purchase of 46,511 shares on December 18. This move, following earlier 2025 buys totaling ~$1M, signals strong executive conviction in the company’s clinical pipeline, particularly varegacestat’s recent registrational study results. Siegall’s track record as Seagen’s co-founder—leading its $43B acquisition by Pfizer—adds credibility to his investment. The purchase coincided with positive biotech sector momentum, as AMGN’s 1.35% rise underscored renewed investor appetite for oncology innovation.

Biotech Sector Gains Momentum as AMGN Leads
The biotech sector’s broader strength, with AMGN rising 1.35%, amplifies Immunome’s rally. While AMGN’s growth stems from its diversified oncology and biosimilars portfolio, Immunome’s surge is driven by targeted clinical progress and insider accumulation. The sector’s 1.35% gain suggests a favorable risk-on environment for biotech innovators, though Immunome’s 7.8% move outpaces AMGN’s, reflecting its speculative nature and CEO-driven catalyst.

Options Playbook: High-Leverage Calls for Biotech Bullishness
• MACD: 1.10 (above signal line 1.095), RSI: 55.01 (neutral), Bollinger Upper: $22.45 (near current price)
• 200D MA: $11.22 (far below), 30D MA: $18.60 (support level), 100D MA: $13.92

Immunome’s technicals suggest a short-term bullish bias, with the stock trading near its 52-week high and RSI in neutral territory. Key levels to watch include the 200D MA ($11.22) as a critical support and the 30D MA ($18.60) as a potential reentry point. The biotech sector’s momentum, led by AMGN’s 1.35% rise, supports a continuation of the rally.

Top Options Picks:
• IMNM20260116C22 (Call, $22 strike, Jan 16 2026):
- IV: 85.05% (high volatility)
- Leverage: 11.87% (moderate)
- Delta: 0.505 (moderate sensitivity)
- Theta: -0.048 (rapid time decay)
- Gamma: 0.0778 (high sensitivity to price swings)
- Turnover: $9,204
- Payoff at 5% upside ($22.58): $0.58/share gain
This contract offers a balance of leverage and gamma, ideal for capitalizing on a continuation of the rally while managing time decay.

• IMNM20260116C24 (Call, $24 strike, Jan 16 2026):
- IV: 81.97% (high volatility)
- Leverage: 20.36% (high)
- Delta: 0.355 (moderate sensitivity)
- Theta: -0.041 (rapid time decay)
- Gamma: 0.0754 (high sensitivity to price swings)
- Turnover: $4,996
- Payoff at 5% upside ($22.58): $0.58/share gain
This high-leverage call benefits from elevated gamma and IV, making it a speculative play for aggressive bulls expecting a breakout above $24.

Trading Insight: Aggressive bulls may consider IMNM20260116C22 into a test of the 52-week high ($25.30), while IMNM20260116C24 offers outsized returns if the stock breaks above $24.

Backtest Immunome Stock Performance
The backtest of IMNM's performance following an 8% intraday surge from 2022 to the present shows favorable results. The 3-Day win rate is 48.85%, the 10-Day win rate is 51.57%, and the 30-Day win rate is 57.86%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest was 18.21%, which occurred on day 59, suggesting that IMNM has the potential for significant gains following the 8% surge.

Act Now: Ride the Biotech Bull Wave or Secure Profits
Immunome’s 7.8% surge, fueled by CEO conviction and sector momentum, presents a high-conviction trade for biotech bulls. The stock’s proximity to its 52-week high and elevated gamma in options like IMNM20260116C22 suggest a continuation of the rally is likely, provided the $22.45 Bollinger Upper level holds. AMGN’s 1.35% rise reinforces the sector’s strength, making now the optimal time to secure exposure via high-leverage calls or tighten stop-losses on long positions. Watch for a breakdown below $19.43 (middle Bollinger Band) to signal a reversal.